Merck in talks to buy biotech Revolution Medicines, FT reports
Jan 8 (Reuters) - Merck is in talks to buy cancer drug developer Revolution Medicines, the Financial Times reported on Thursday, citing people familiar with the matter.
Shares of Revolution were up 5.2% in afternoon trading.
Merck has been pursuing an acquisition of Revolution Medicines, however, a deal has not been finalised, the report said, adding a tie-up would be at least several weeks away.
Other large pharmaceutical groups were still circling the biotech and another suitor might yet prevail, the FT report said.
Merck and Revolution Medicines did not immediately respond to Reuters' requests for comment.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Macron pushes EU to activate anti-coercion tool against US tariffs
Euro Weakness From Trump Capped Due to Limited US Asset Holdings, Says Deutsche
Hassett Suggests Trump Could Be Justified in Overlooking Him for Fed Chair
Top 10 DeFAI Projects: $PAAL and $SWARMS Leads the Pack by Social Activity
Trending news
MoreCrypto prices
More
